CDHA CAAR

“CMS Should Strengthen Its Prescription Drug Event Guidance To Clarify Reporting of Sponsor Margin for Medicare Part D Bids,” (A-03-17-00001, November 2021, .pdf format, 15p.).

oig.hhs.gov/oas/reports/region3/31700001.asp

“How Would Drug Price Negotiation Affect Medicare Part D Premiums?” by Juliette Cubanski and Tricia Neuman (August 2021, .pdf and HTML format, 3p.).

www.kff.org/medicare/issue-brief/how-would-drug-price-negotiation-affect-medicare-part-d-premiums/

A. “Drug Price Increases That Exceed Inflation Are Costing Medicare Part D Billions,” by Leigh Purvis (June 2021, .pdf format, 5p.).

www.aarp.org/ppi/info-2021/drug-price-increases-that-exceed-inflation-are-costing-medicare.html

B. “Rx Price Watch Report: Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans, 2006 to 2020,” by Leigh Purvis and Dr. Stephen Schondelmeyer (June 2021, .pdf format, p.).

www.aarp.org/ppi/info-2019/trends-in-retail-prices-of-drugs.html

“Relatively Few Drugs Account for a Large Share of Medicare Prescription Drug Spending,” by Juliette Cubanski and Tricia Neuman (April 2021, HTML format).

www.kff.org/medicare/issue-brief/relatively-few-drugs-account-for-a-large-share-of-medicare-prescription-drug-spending/

“Price Increases Continue to Outpace Inflation for Many Medicare Part D Drugs,” by Juliette Cubanski and Tricia Neuman (February 2021, HTML format).

www.kff.org/medicare/issue-brief/price-increases-continue-to-outpace-inflation-for-many-medicare-part-d-drugs/

“Prescription Drugs: Department of Veterans Affairs Paid About Half as Much as Medicare Part D for Selected Drugs in 2017,” (GAO-21-111, December 2020, .pdf format, 23p.).

www.gao.gov/products/GAO-21-111

“Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2021,” by Juliette Cubanski and Anthony Damico (October 2020, HTML format).

www.kff.org/medicare/issue-brief/medicare-part-d-a-first-look-at-medicare-prescription-drug-plans-in-2021/

“Loophole in Drug Payment Rule Continues To Cost Medicare and Beneficiaries Hundreds of Millions of Dollars,” (OEI-BL-20-00100, July 2020, .pdf format, 16p.).

oig.hhs.gov/oei/reports/OEI-BL-20-00100.asp

“Examining Current Medicare Part D Policies for Extended Supplies of Medication,” by Juliette Cubanski, Karyn Schwartz, and Anthony Damico (March 2020, HTML format).

www.kff.org/medicare/issue-brief/examining-current-medicare-part-d-policies-for-extended-supplies-of-medication/

“A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries,” by Meredith Freed, Juliette Cubanski, and Tricia Neuman (November 2019, .pdf and HTML format, 27p.).

www.kff.org/medicare/issue-brief/a-look-at-recent-proposals-to-control-drug-spending-by-medicare-and-its-beneficiaries/

“Assessing Drug Price Increases in Medicare Part D and the Implications of Inflation Limits,” by Juliette Cubanski and Tricia Neuman (October 2019, .pdf format, 6p.).

www.kff.org/medicare/issue-brief/assessing-drug-price-increases-in-medicare-part-d-and-the-implications-of-inflation-limits/

“Key Provisions of Proposals on Drug Price Negotiation, Inflation Rebates, and Medicare Part D Redesign,” (September 2019, .pdf and HTML format, 2p.).

www.commonwealthfund.org/publications/2019/sep/key-provisions-proposals-drug-price-negotiation-inflation-rebates-part-d-redesign

“Medicare Part D’s Effect on Evergreening, Generics, and Drug Prices,” by Geoffrey T. Sanzenbacher and Gal Wettstein (IB No. 19-14, September 2019, .pdf and Excel format, 7p.).

crr.bc.edu/briefs/medicare-part-ds-effect-on-evergreening-generics-and-drug-prices/

“Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2017 Average Sales Prices,” (OEI-03-19-00260, August 2019, .pdf format, 12p.).

oig.hhs.gov/oei/reports/oei-03-19-00260.asp

“A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries,” by Meredith Freed, Juliette Cubanski, and Tricia Neuman (August 2019, HTML and .pdf format, 27p.).

www.kff.org/medicare/issue-brief/a-look-at-recent-proposals-to-control-drug-spending-by-medicare-and-its-beneficiaries/

“How Many Medicare Part D Enrollees Had High Out-of-Pocket Drug Costs in 2017?” by Juliette Cubanski, Tricia Neuman, and Anthony Damico (June 2019, .pdf format, 12p.).

www.kff.org/medicare/issue-brief/how-many-medicare-part-d-enrollees-had-high-out-of-pocket-drug-costs-in-2017/

“The Effect of Medicare Part D on Evergreening, Generic Entry, and Drug Prices,” by Geoffrey T. Sanzenbacher and Gal Wettstein (WP No.2019-8, May 2019, .pdf and Excel format, 24p.). Note: Links to the abstract and the full text of this paper available at:

crr.bc.edu/working-papers/the-effect-of-medicare-part-d-on-evergreening-generic-entry-and-drug-prices/

“The Out-of-Pocket Cost Burden for Specialty Drugs in Medicare Part D in 2019,” by Juliette Cubanski, Wyatt Koma, and Tricia Neuman (January 2019, .pdf and HTML format, 16p.).

www.kff.org/medicare/issue-brief/the-out-of-pocket-cost-burden-for-specialty-drugs-in-medicare-part-d-in-2019/

“Proposed Changes to Medicare Part D Would Benefit Drug Manufacturers More Than Beneficiaries,” by Shawn Bishop (January 2019).

www.commonwealthfund.org/blog/2019/proposed-changes-medicare-part-d-would-benefit-drug-manufacturers-more-beneficiaries